Neuro-oncologists and neurosurgeons constantly face challenging clinical decisions when managing patients with intracranial malignancies following definitive radiotherapy or stereotactic radiosurgery. Applying a sensitive liquid biopsy brain tumor assay offers an innovative non-invasive solution to resolve post-treatment diagnostic dilemmas. Consequently, clinicians must reliably distinguish true disease progression from treatment-induced tissue changes such as pseudoprogression and late radiation necrosis. Conventional neuroimaging modalities frequently fail to differentiate these distinct pathophysiological entities with sufficient diagnostic precision. Although surgical resection and stereotactic tissue biopsy provide definitive histopathological confirmation, invasive procedures carry substantial risks of neurological morbidity and patient distress. Therefore, molecular surveillance utilizing peripheral biofluids represents a major leap forward for neuro-oncology practice.

The Diagnostic Dilemma: True Progression Versus Treatment Effects

Radiation therapy and radiosurgery alter the cerebral microenvironment significantly, inducing intense local inflammation, endothelial cell injury, and localized blood-brain barrier disruption. In malignant gliomas and brain metastases, these radiation-induced alterations often manifest as enlarging contrast-enhancing lesions on routine post-treatment magnetic resonance imaging. Clinicians classify these radiographic changes either as transient pseudoprogression, which typically occurs within weeks to months, or delayed radiation necrosis, which can arise years following radiation delivery. Because both conditions mimic active neoplastic proliferation, physicians frequently struggle to select the appropriate clinical management pathway. For example, misdiagnosing radiation-induced necrosis as tumor recurrence can lead to premature cessation of effective anti-tumor regimens or unnecessary surgical re-interventions. Conversely, mistaking true disease recurrence for benign radiation necrosis delays essential salvage chemotherapy, target re-irradiation, or enrollment in investigative clinical trials. Advanced radiological approaches, including perfusion MRI, magnetic resonance spectroscopy, and metabolic amino acid PET imaging, have improved diagnostic accuracy. Nevertheless, these imaging technologies still yield ambiguous results when microscopic recurrence intermingles with severe radiation-damaged tissue. Thus, clinicians urgently require objective, repeatable, and biologically specific biomarkers to monitor intracranial tumors accurately.

Emerging Biomarkers in Liquid Biopsy Brain Tumor Surveillance

Recent systematic evaluation reveals that investigators have tested an expansive array of liquid biopsy substrates to differentiate active tumor proliferation from radiation-induced changes. Specifically, circulating tumor cells, cell-free DNA fragments, mitochondrial DNA levels, and specific retrotransposon B1-SINE elements demonstrate measurable variance across patient cohorts. Furthermore, circulating immune cell subsets provide vital clues regarding systemic inflammatory responses versus immunosuppressive tumor microenvironments. Researchers have paid particular attention to monocytic myeloid-derived suppressor cells expressing HLA-DR and VNN2 markers, which fluctuate significantly during distinct clinical phases. Similarly, circulating immune-related signaling proteins, such as CXC motif chemokine 11 (CXCL11) and mucin-16 (MUC-16), offer functional insight into the host inflammatory response versus progressive intracranial malignancy. In addition, tumor-derived microvesicles and extracellular vesicle-encapsulated RNA analytes cross the compromised blood-brain barrier into peripheral circulation, providing real-time transcripts of underlying tumor biology. When clinicians evaluate these molecular targets dynamically, quantitative shifts frequently mirror therapeutic responsiveness long before anatomical alterations become radiographically evident. Therefore, molecular profiling through peripheral blood or proximal cerebrospinal fluid captures the underlying biology of resolving inflammation versus aggressive neoplastic regrowth with unprecedented detail.

Analytical Platforms and Biofluid Selection

The clinical implementation of liquid biopsy techniques in neuro-oncology relies heavily on selecting appropriate biofluids and analytical platforms. Currently, peripheral blood plasma remains the most widely investigated biofluid because routine phlebotomy provides easy accessibility, excellent patient tolerability, and low procedural risk. However, the physiological blood-brain barrier naturally restricts the passage of macromolecules, yielding lower concentrations of circulating tumor material compared to systemic cancers. Consequently, researchers are actively investigating alternative biofluids such as cerebrospinal fluid, which directly bathes the central nervous system and provides enriched concentrations of tumor-derived nucleic acids. Urine has also emerged as a non-invasive biofluid for detecting fragmented circulating cell-free DNA, although clinical studies remain scarce. Simultaneously, analytical methodologies have evolved beyond basic detection to include high-sensitivity multiplex protein profiling, advanced multi-color flow cytometry, digital droplet PCR assays, and targeted next-generation sequencing. Furthermore, investigators combine immunostaining with fluorescence in situ hybridization to identify rare circulating tumor cell populations. Although these advanced technical platforms provide impressive analytical sensitivity, clinical laboratories must establish uniform processing protocols, rigorous validation standards, and quality controls to guarantee reproducibility across diverse institutional settings.

Diagnostic Accuracy of Composite Indices and Biomarker Models

Single biomarkers often lack sufficient diagnostic sensitivity and specificity when isolated, because intracranial radiation necrosis and true recurrence both produce complex inflammatory cascades. Therefore, translational investigators have constructed multi-parametric scoring tools to integrate distinct immunological and molecular variables into robust predictive algorithms. Among these innovative models, the DR-VNN2 Index (DVI) combines specific myeloid cell phenotypes to accurately discriminate between post-radiation inflammatory damage and active glioblastoma regrowth. Similarly, the Necrosis Prediction Index (NPI) synthesizes circulating protein concentrations and immune metrics, demonstrating significant potential for identifying radiation necrosis before patients undergo invasive surgical procedures. By combining orthogonal biological features, these composite diagnostic panels substantially reduce false-positive rates and enhance clinical confidence. In comparative studies, composite indices consistently outperform individual circulating analytes, achieving superior area-under-the-curve metrics in discrimination tests. Consequently, multi-analyte algorithms enable multidisciplinary neuro-oncology tumor boards to make informed treatment decisions, optimizing steroid tapering, vascular endothelial growth factor inhibitor administration, or surgical scheduling based on individualized molecular probabilities.

Current Limitations and Future Directions in Neuro-Oncology

Despite encouraging findings, significant hurdles must be resolved before liquid biopsy enters mainstream neuro-oncology guidelines. First, the majority of available data originates from retrospective, small single-center cohorts that lack standardized diagnostic reference criteria. In addition, wide methodological variations in sample collection, timing of venipuncture relative to radiotherapy, and analytical thresholds impede direct cross-study comparisons. Many published reports also report incomplete diagnostic performance metrics, omitting crucial values such as negative predictive power and clinical sensitivity. Furthermore, the high economic cost and infrastructure requirements for specialized sequencing platforms pose practical barriers for routine adoption in resource-conscious health systems. To overcome these limitations, international collaborative groups must initiate large-scale, prospective, multicenter clinical validation trials. Researchers must standardize pre-analytical handling protocols and directly correlate longitudinal biofluid signatures with matched tissue pathology and long-term overall survival outcomes. When combined with advanced radiomics and artificial intelligence algorithms, validated liquid biopsy panels will ultimately provide a reliable, minimally invasive paradigm for personalized neuro-oncology care.

What is the primary clinical advantage of liquid biopsy over conventional neuroimaging?

Liquid biopsy provides objective molecular and immunological data regarding active tumor biology and host inflammation. Unlike conventional neuroimaging, which frequently shows ambiguous contrast enhancement in both tumor recurrence and radiation injury, liquid biopsy non-invasively differentiates active neoplastic cellular turnover from sterile radiation-induced tissue necrosis without requiring high-risk cranial surgery.

Which biofluid is currently most useful for liquid biopsy in brain tumors?

Peripheral blood plasma is the most widely utilized biofluid due to its minimal invasiveness, high patient acceptability, and ease of serial collection. However, cerebrospinal fluid often contains significantly higher concentrations of tumor-derived cell-free DNA because it directly contacts the cerebral parenchyma, bypassing the restrictive blood-brain barrier.

Why are composite biomarker indices preferred over single molecular markers?

Intracranial tumor recurrence and radiation necrosis share overlapping biological pathways, including vascular disruption and local inflammation. Consequently, single markers rarely provide adequate diagnostic accuracy. Composite indices, such as the DR-VNN2 Index, integrate multiple immune phenotypes and molecular analytes simultaneously, substantially improving diagnostic specificity and clinical predictive power.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Clinical decisions should always be made by qualified healthcare professionals based on individual patient evaluations and applicable clinical circumstances. Refer to the latest local and national guidelines for clinical practice.

References

1. Izhar M et al. Clinical utility of liquid biopsy in distinguishing true progression from radiation necrosis and pseudoprogression in malignant brain tumor. J Neurooncol. 2026 May 25. doi: 10.1007/s11060-026-05618-z. PMID: 42185659.


2. Nassiri F, Chakravarthy A, Wang S, et al. Detection and surveillance of central nervous system tumors using cerebrospinal fluid cell-free DNA methylation. Nat Med. 2020;26(7):1044-1047.


3. Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ. Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol. 2017;134(3):495-504.